Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran.
METHODS
Masih Daneshvari Hospital, Tehran, Iran, 2000-2002.


OBJECTIVE
To evaluate the effectiveness of multiple drug-resistant tuberculosis (MDR-TB) treatment for the first time in Iran.


METHODS
All cases of MDR-TB with complete follow-up data were recruited and results of their treatments were evaluated.


RESULTS
MDR-TB treatment was initiated with 5.23 drugs, on average. Isoniazid, amikacin, and ofloxacin were present in the drug regimen of all patients. Average duration of the treatment was 18.5 months (range, 7-36). Over 76% of the patients responded to the treatment (negative smear and culture). Cure and probable cure were documented in seven (41.2%) and four (23.5%) of the patients, respectively. No failure in the treatment occurred when cycloserine was present in the treatment regimen.


CONCLUSIONS
A majority of the MDR-TB patients in Iran can be cured with the use of appropriate treatment regimens. An even greater success could be achieved by providing more second-line drugs.
Mirsaeidi
Seyed Mehdi
SM
Department of Tuberculosis and Respiratory Infections, Iranian National Research Institute of Tuberculosis and Lung Diseases, Tehran 19556, Iran. mmirsaeidi@nritld.ac.ir
Tabarsi
Payam
P
Khoshnood
Kaveh
K
Pooramiri
Majid Valiollah
MV
Rowhani-Rahbar
Ali
A
Mansoori
Seyed Davood
SD
Masjedi
Heydar
H
Zahirifard
Soheyla
S
Mohammadi
Foroozan
F
Farnia
Parisa
P
Masjedi
Mohammad Reza
MR
Velayati
Ali Akbar
AA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000583:Amikacin / Q000008:administration & dosage / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use*; D003523:Cycloserine / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007492:Iran; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000382:microbiology
D000995:Antitubercular Agents; D000583:Amikacin; D003523:Cycloserine; D015242:Ofloxacin; D007538:Isoniazid